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Clinical Question 
What is the best treatment for anogenital molluscum contagiosum? 
Evidence-Based Answer 
There is no evidence from comparative trials to suggest a single best treatment method for 
anogenital molluscum contagiosum. Randomized controlled trials suggest self-administered 
topical imiquimod or podophyllotoxin cream is effective for resolving lesions. (Strength of 
Recommendation: B, based on inconsistent or limited quality patient-oriented evidence). There 
are no comparative trials of other commonly used treatments, such as carbon dioxide laser, 
cryotherapy, or curettage. 
Evidence Summary 
Molluscum contagiosum virus mainly affects children, persons who are sexually active, and 
persons who are immunocompromised.1 It is a double-stranded DNA virus in the Poxviridae 
family and is usually a self-limited disease.2 Molluscum contagiosum virus is recognized as a 
sexually transmitted disease in adults and currently accounts for almost 1 percent of all 
diagnosed dermatologic conditions.3 Between 5 and 18 percent of persons with human 
immunodeficiency virus are coinfected with molluscum contagiosum virus.3 Without treatment, 
lesions may take six months to five years to disappear; therefore, some experts recommend 
treatment of anogenital lesions to reduce the risk of sexual transmission, prevent autoinoculation, 
and increase quality of life.4,5 
Although numerous treatments for molluscum contagiosum virus exist, few have strong evidence 
to support their use. Most published studies are not placebo-controlled trials. Treatment can be 
physician- or patient-administered and may utilize mechanical, chemical, or immunologic 
mechanisms.4,6 Carbon dioxide laser, cryotherapy, and curettage are commonly used to remove 
molluscum contagiosum virus lesions; however, there is no evidence of their effectiveness for 
treatment of anogenital lesions.7  
A randomized, double-blind, placebo-controlled trial of men (n = 100) evaluated imiquimod 1% 
cream self-applied three times daily for five consecutive days per week for four weeks (60 total 
applications).8 Ages of the participants ranged from nine to 27 years (mean of 16.3 years). 
Patients had an average of 7.3 lesions, ranging from 2 to 5 mm in diameter (mean of 3.4 mm). 
The generalizability of the trial was limited by its exclusion of women and men older than 28 
years. Ninety percent of lesions were located on the patients' genitalia or thighs. At one year, 
total resolution of lesions occurred in 82 percent of patients in the treatment group versus 16 
percent in the placebo group (P < .001; number needed to treat [NNT] = 1.5). Mild, subjective 
adverse effects were reported in 18 percent of patients in the treatment group versus 6 percent in 
the placebo group (number needed to harm = 8.3). Imiquimod is typically not recommended for 
pregnant women (U.S. Food and Drug Administration pregnancy category C).  
A randomized, double-blind, placebo-controlled, multicenter trial of men (n = 150) evaluated the 
use of self-administered topical podophyllotoxin 0.3% and 0.5% creams.9 Men 10 to 26 years of 
age with biopsy-proven molluscum contagiosum virus lesions on the face, arms, thighs, or 
anogenital region were evaluated after twice-daily application of podophyllotoxin 0.3% or 0.5% 
cream or placebo for three consecutive days. If lesions were persistent, the same treatment was 
continued for three more weeks. Complete resolution of lesions occurred in 15 percent of all 
patients following the initial application trial. At the end of four weeks, 92 percent of patients in 
the podophyllotoxin 0.5% cream group (NNT = 1.3), 52 percent in the podophyllotoxin 0.3% 
cream group (NNT = 2.8), and 16 percent in the placebo group had full resolution of lesions. 
Twice-daily use of podophyllotoxin 0.5% cream was more effective than twice-daily use of the 
0.3% formulation (P < .001).9 
Recommendations from Others 
A comprehensive review of medical and professional associations revealed no official guidelines 
regarding treatment of anogenital molluscum contagiosum. A Cochrane review addressed 
treatment for general cutaneous molluscum contagiosum virus lesions; however, it specifically 
excluded anogenital molluscum contagiosum in the analysis.7 For generalized cutaneous 
molluscum contagiosum virus, there is insufficient evidence to support any single therapy, but 
expert opinion favors physical destruction of lesions. Authoritative textbook authors recommend 
various treatments for anogenital molluscum contagiosum (i.e., curettage, cryosurgery, antiviral 
or immunomodulatory medication, cantharidin, potassium hydroxide, oral cimetidine [Tagamet], 
laser therapy, and trichloroacetic acid), but do not endorse any single treatment regimen.5 
Traditional therapies, such as carbon dioxide laser, cryotherapy, or curettage, should be 
considered in pregnant women.6 
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